Background: Studies of Antiretroviral Therapy program in Africa have shown high incidence rate of opportunistic infections in both Antiretroviral Therapy receiving and Pre ART Human Immunodeficiency Virus infected patients. However, incidence of opportunistic infections and factors that contribute for development of it were poorly described in Ethiopia especially in the study area.
Introduction
According to the latest United Nation's Agency for International Development (UNAID) estimate, about 34 million people were living with human immunodeficiency virus (HIV) in 2011 [1, 2] . Globally, the annual number of people dying from acquired immunodeficiency syndrome (AIDS)-related causes was 1.7 million in 2011 [3] .
According to 2011 Ethiopian demographic health survey, the overall national adult (age 15-49 years) HIV prevalence was 1.5% (1% among males and 1.9% among females) and 0.9% for SNNPR [4] . Introduction of combination antiretroviral therapy in 1996 has led to dramatic reductions in morbidity and mortality from HIV/AIDS [1, 2] . In Ethiopia, the fee based and universal free access antiretroviral (ARV) treatment was started in 2002/3 and 2004/5 respectively [5, 6] .
Ethiopia has been engaged in the scale-up of ART access to its people since 2005. Despite challenges like poor health infrastructure, lack of state of the ART diagnostic tools, and shortage of health care providers, ART scale-up has recorded the greatest achievement in the number of people reached and facilities providing these services over the last few years. The number of sites providing the ART service had increased from 3 to 874 and people started on treatment increased from 24,000 to 308,000 from 2006 to 2012 [7] .
Opportunistic infections (OIs) are diseases that rarely occur in healthy people but cause infections in individuals whose immune systems are compromised, including by HIV infection. Organisms that cause OIs are frequently present in the body but are generally kept under control by a healthy immune system. HIV gradually weakens a person's immune system and leads to the development of one or more opportunistic infections, which signals the progression to AIDS. These illnesses are generally the eventual cause of death due to HIV infection [8] .
OIs can occur in about 40% of people living with HIV (PLHIV) with a CD4 count less than 250/mm 3 [9] . About 39.1% of the patients already had an opportunistic infection, which was the first manifestation of immune suppression caused by HIV. Of the total of opportunistic infections, 74.2% occurred in the non-HAART group, in the HAART group there were 25.8% episodes of opportunistic infections recorded, 83.6% of who were using the first regimen of combined therapy [10] .
Sample size determination
The sample size was calculated based on the assumption of 95% confidence interval and 80% power for two population proportion formula with one to one ratio for HAART and pre-ART PLWHIV using the proportions of OIs,74.2% for Pre ART and 25.8 % HAART PLHIV respectively [10] . Epi info version 3.5.1 is used to calculate the sample size.
Where: n 1 = number of HIV infected patients who are Pre ART (non exposed) n 2 = number of HIV infected patients who are on ART (Exposed) r=the ratio of exposed to non exposed HIV infected patients=1 P 1 = proportion of OIs in HAART receiving HIV infected patients P 2 = proportion of OIs in Pre ART HIV infected patients Z α/2 : 1.96 at 95% confidence interval Accordingly, the calculated sample size was 422 (211 for HAART and Pre ART); after adding 10% contingency the total sample size was 464, 232 patients for each cohort (Figure 1 ).
Data collection and quality control
Data collection format was developed from federal ministry of health HIV care/ART follow up form which is used in the ART clinic and also the patients' card; the format includes the following check list:
• socio-demographic characteristics (sex, age, residence, marital status, occupational status, educational status);
• ART and chemoprophylaxis information (ARV drug treatment, drug adherence, line of treatment regimen, prophylaxis treatment and its adherence);
• laboratory information (CD4 count, hemoglobin value);
• Clinical information (WHO clinical staging, weight, height); and • Functional status of patients (working, ambulatory, bedridden).
The data was collected by reviewing HIV care/ART follow up form, laboratory requests and patients' card. To ensure the quality of data, data collectors are trained nurses, recruited from ART clinic on method of extracting the needed data from patient's records and filling on data collection format. On the days of data collection, the principal investigator and the supervisor supervises the data collection process by checking completeness of the data. Three data collectors and one supervisor who had direct experience and working on ART clinic was recruited for data collection and supervision respectively. Data collectors and supervisor was trained on objectives of the study, selection of exposed and unexposed, how to keep confidentiality of information, the contents of the questionnaire and data quality management by the principal investigator. Individuals who drop-out, loss to follow-up, transferred out, dead by any disease other than OI where cause of death not confirmed during study period or not develop any OI at the end of the study period was considered as censored.
Data processing and analysis
The data collection form was checked for completeness and consistency by the principal investigator before data entry. Completed data abstraction form was coded by numbers and entered in computer software EPI info version 3.5.1 statistical package and exported to SPSS version 16 and STATA version 11 for analysis. The risk of developing OIs among patients with retrospective follow up in Pre ART or HAART cohort was assessed using the person-year method. Incidence rate was calculated as number of OIs cases per 100 person year observed. Cox proportional hazards model was used to assess predictors of incidence of OIs, the Kaplan-Meier technique and the generalized log-rank test 31(6.7%) lost to follow up/drop out, 22(4.7%) transfers out, 9(1.9) deaths and 225(48.5%) HIV positive people didn't develop OI up to the end of the study. 197 (85%) have good adherence to drugs, 196 (42.2%) were not taking any prophylaxis, 171(73.7%) started HAART when they fulfill CD4 count criteria only. Concerning the type of HAART the patient takes all took first line HAART and at baseline around 40.9% of patients were taking Tenofevir, Lamivudine and Efaverenz combination while around 20 % were taking Stavudine, Lamivudine and Nevirapine and there rest took other combinations ( Table 2) .
Comparison of OIs incidence rate and OIs free survival in Pre ART and HAART cohorts
All the 464 study subjects have contributed for their respective group OI free time follow up observation 279.39 PY and 618.73 PY in Pre-ART and HAART cohort respectively. In Pre-ART cohort more HIV infected patients developed OI (156) than ART cohort [11] with the incidence rate of 55.8 per 100 PY and 3.4 per 100 PY respectively. Overall probability of not developing OIs in the HAART cohort was significantly greater than that of the Pre-ART cohort, i.e. the risk of developing OIs is higher in Pre-HAART group (P<0.001) ( Figure 2 ).
In HAART cohort, from those who developed OI, around 57% of OI cases occur in the first two years of follow up but in the Pre ART 56.4% of the OI cases occurred in the first one year. Based on the life table analysis the probability of not developing OI at one, two, three and four year in HAART cohort were 96%, 94%, 90% and 88% respectively. The corresponding values in Pre-ART cohort were 58%, 41%, 24%, and 8% respectively. This clearly showed that the probability of not developing OI at the end of study period in Pre-ART cohort was lower than that of HAART cohort (0% Vs 82% respectively) ( Table 3) .
Predictors of OIs incidence
Before fitting the covariate into the model all the proportional hazard assumptions were checked by Schoenfeld residual and by examining log minus log plots. To identify independent predictors of developing OI, a multivariate Cox-Proportional hazard adjusted model were used to construct and compare the OIs-free survival probabilities curves of the two groups. Pre ART PLWHIV: The person whose HIV positive status confirmed but not eligible for ART;
Study variables
HAART PLWHIV: The person whose HIV positive status confirmed and started ART;
Survival: The person without any OI occurrence Censored: Non-occurrence of any OI in study participant during follow-up study but not sure for future occurrence;
Drop out: If a PLWHIV on HIV care lost to follow up for more than three months as recorded by ART clinic personnel;
Lost to follow up: If PLWHIV on HIV care not seen for equal to or more than one month as recorded by ART clinic personnel;
Transferred out: If PLWHIV on HIV care in one health institution shift to other health institution;
Ethical considerations
Ethical clearance was obtained from the Ethical Review Committee (ERC) of ACIPH before conducting the study. After securing ethical clearance from ERC ACIPH, Arba Minch Hospital and Health center was informed about the objective of the study and written consent was obtained. To keep the confidentiality of the patients, data collectors was recruited from ART clinic and personal identifiers were not included in the data abstraction format and the information collected for this research kept confidential.
Result

Socio-demographic characteristics of the study subjects
Majority of the participants (64%) are female and 79% are urban residence. More than one third (38.1%) of the patients were in the age range between 25 and 34 years with median age (± SD) of 30 (± 9.8). (Table 1) 
Baseline and follow up characteristics of HIV infected patients in Arba Minch town, 2014
In this retrospective cohort study there were 177(38.2%) OI cases, Another important predictor of OI incidence was being on substance user or not. The risk of developing OI in individuals who was using substance at baseline and follow up is nearly two times higher than that of non user cohorts (P<0.001). Study subjects with baseline CD4 count between 350 -499 cells/µl is nearly two times higher than those with greater than or equal to 500 cells/µl (p=0.004) but baseline CD4 count of <200 cells/µl and 200-349 cells/µl is not associated with OI incidence with p value of 0.792and 0.694 respectively. Taking HAART is preventive of OIs occurrence (AHR= 0.07, 95% CI=0.03-0.16, P<0.001 (Table 4 ).
Discussion
In this retrospective cohort study, 156 (67.2%) of the participants had occurrence of OIs in the pre ART cohort and 21(9.1 %) in the HAART cohort. The overall incidence of OIs was 19.7 per 100 PY. The incidence of OIs showed a decline from 55.84/100 PY (95% CI: 47.58, 65.13) in those patients not using HAART to 3.39/100 PY (95%CI: 2.157, 5.1) in those using HAART. Being widowed than married, male gender, substance use, rural residence and having baseline CD4 count of 350-499 cells/µl and follow up CD4 count other than Above 500 cells/ µl were factors increased occurrence of OIs; however, the preventive factors were taking HAART and not being in the age range 15-24.
This study showed that, 156 (67.2%) of the participants had occurrence of OIs in the pre ART cohort and 21(9.1 %) in the HAART cohort. This is in line with a study in Taiwan which said 8% of patients developed OI after HAART. However the proportion of OIs is lower than a study conducted in Brazil in which the proportion of OI in pre ART and HAART cohort was 74.2%, 25.8% respectively. This decrement may be due to the fact that the current study includes only adults but the previous study includes children who may have lower immunity than adults and may lead to increased proportion of OIs. result from Coˆ te d'Ivoire shows higher rate of OIs because of the study includes a wide range of bacterial disease which were not included in this study so which might have overestimated the incidence density rate [12, 13] .
The incidence of OIs showed a decline from 55.84/100 PY (95%CI: 47.58, 65.13) in those patients not using HAART to 3.39/100 PY (95%CI: 2.157, 5.1) in those using HAART. Which is lower than a study conducted in Brazil 113.73/100 PY (95%CI: 102.24-126.46) in those patients not using HAART to 41.30/100 using HAART. This is due to the study conducted in Brazil includes children but the current study includes only adults.
In the present study, the introduction of HAART is associated with a dramatic effect in the overall reduction of incidence rates of OIs in PLWHIV which is supported by different studies [10, [14] [15] [16] [17] .
In analysis of predictor variable patient with widowed marital status was nearly two times at higher risk of developing OIs than patients with marred marital status. This is possibly because of having supporter for timely taking of medication as directed. Male gender was associated with higher incidence of OIs with p<0.001 which is in congruent with a study by Manosuthi W et al in resource limited settings. Having baseline CD4 count <200 and between 200-349 is not associated with occurrence of OIs but CD4 count of between 350-449 was nearly two times higher risk of developing OIs. This may be due to the fact that patients with CD4 count between 350-449 were not taking HAART. Being substance user was more than two times higher risk than non users. This may be due to substance use may cause to take subscribed medications untimely. At follow up patients with CD4 count less than 200 cells/µl; between 200 and 349 cells/ µl, 350 and 449 cells/ µl were at increased risk of developing OI than CD4 count of above 500 cells/ µl. This is in line with studies conducted by different scholars in different countries [14, 18, 19] . Rural residence increased occurrence of OIs nearly two times than being urban residence. This may be due to the fact that urban residence enables for easy access of information how to prevent occurrence of diseases and treatment purpose.
Conclusions
During a median of 1.68 PY of follow up OIs were occurred in one third of study participants (38.1%). The incidence of OIs showed a decline from 55.84/100 PY (95% CI: 47.58, 65.13) in those patients not using HAART to 3.39/100 PY (95%CI: 2.157, 5.1) in those using HAART.
Independent significant predictors that increase occurrence (risk factors) and improve survival (preventive factors) were identified. Those risk factors were being widowed than married, male gender, substance use, rural residence, having baseline CD4 count of 350-499 and follow up CD4 count of other than above 500 cells/µl; however, the preventive factors were taking HAART and not being in age range of 15-24 years. HAART significantly reduced occurrence of OIs so that initiation of HAART even at higher CD4 count has paramount importance.
Recommendations
To hospitals and health centers with ART clinic (giving HIV care and support)
• Since OI were also common in those with higher CD4 count, PLWHIV should be encouraged to take HAART below 500 cells/µl CD4 count.
• Special consideration should focus on high risk groups such as widowed and substance users.
To Arba Minch town health office and other responsible organizations
• Health professionals should be encouraged to properly document patients' healthcare data.
To research and academic institutions
• Further observational studies with prospective design to ascertain the findings are recommended.
